Toward molecular diagnostics of mood disorders in psychiatry

Trends in Molecular Medicine

Volumn 8, Issue 6, 2002, Pages 294-300

  Avissar, Sofia ^a   Schreiber, Gabriel ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AFFECTIVE NEUROSIS; COMORBIDITY; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENOMICS; HUMAN; MOLECULAR BIOLOGY; PATHOPHYSIOLOGY; PROTEOMICS; PSYCHIATRIC DIAGNOSIS; QUANTITATIVE TRAIT LOCUS; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STANDARD; DIAGNOSTIC PROCEDURE; GENETICS; METABOLISM; METHODOLOGY; MOOD DISORDER; PSYCHIATRY;

BIOGENIC AMINE; BIOLOGICAL MARKER; DEXAMETHASONE;

BIOGENIC MONOAMINES; BIOLOGICAL MARKERS; DEXAMETHASONE; GENOMICS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MOOD DISORDERS; PROTEOMICS; PSYCHIATRY; SIGNAL TRANSDUCTION;

EID: 0035988615     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02351-1     Document Type: Review

References (63)

1. Epidemiology
2. Comorbid bipolar disorder and panic disorder in families with high prevalence of bipolar disorder
3. Catechol o-Methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder
4. Reduced G protein functions and immunoreactive levels in mononuclear leukocytes of patients with depression
5. Dynamics of ECT normalization of low G protein function and immunoreactivity in mononuclear leukocytes of patients with major depression
6. Differential G protein measures in mononuclear leukocytes of patients with bipolar mood disorder are state dependent
7. The effects of seasons and light therapy on G proteins levels in mononuclear leukocytes of patients with seasonal affective disorder
8. Neuroendocrine, polysomnographic and psychometric observations in healthy subjects at high familial risk for affective disorders: The current state of the 'Munich vulnerability study'
9. Genetic associations with clinical characteristics in bipolar affective disorder and recurrent unipolar depressive disorder
10. Should a biologic marker be sensitive and specific?
11. Recent studies on norepinephrine systems in mood disorders
12. The serotonin hypothesis of major depression
13. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: Evidence in support of the catecholamine hypothesis of mood disorders
14. Association between the tryptophan hydroxylase gene and manic-depressive illness
15. Association study of the tryptophan hydroxylase gene and bipolar affective disorder using family-based internal controls
16. A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22
17. Association between a functional polymorphism in the monoamine oxidase A gene promotor and major depressive disorder
18. Association between bipolar disorder and monoamine oxidase A gene polymorphism: Results of a multicenter study
19. A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder
20. Mood disorders: Neurobiology
21. Mood disorders: Biochemical aspects
22. The dexamethasone suppression test and suicide prediction
23. The role of corticotropin-releasing factor in depression and anxiety disorders
24. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: The first 20 patients treated
25. Association and linkage studies of CRH and PENK genes in bipolar disorder: A collaborative IGSLI study
26. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex
27. Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes
28. The role of G proteins in the psychobiology and treatment of affective disorders and their integration with the neurotransmitter hypothesis
29. Effects of chronic lithium and carbamazepine treatment on G protein subunit expression in rat cerebral cortex
30. Hippocampal and cortical G protein (gs alpha, Go alpha and Gi2 alpha) mRNA expression after electroconvulsive shock or lithium carbonate treatment
31. High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder
32. Change in platelet GTP-binding protein in drug-free depressed patients
33. Mononuclear leukocyte levels of G proteins in depressed patients with bipolar disorder or major depressive disorder
34. Density of guanine nucleotide binding proteins in platelets of patients with major depression
35. The effect of clinical outcome on platelet G proteins of major depressed patients
36. Post mortem cerebral cortex Gs-alpha subunit levels are elevated in bipolar affective disorder
37. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects
38. Elevated dopamine receptor-coupled Gs protein measures in mononuclear leukocytes of patients with schizophrenia
39. G proteins as a biochemical tool for diagnosis and monitoring treatments of mental disorders
40. G protein levels and function as an objective measure of depression in patients with functional bowel disorders
41. The involvement of G proteins in the pathogenesis and treatment of affective disorders
42. Differential effects of the antipsychotics Haloperidol and Clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia
43. No abnormality in the gene for the G protein stimulatory alpha subunit in patients with bipolar disorder
44. Human G (olf) gene polymorphisms and vulnerability to bipolar disorder
45. Genetic analysis of bipolar disorder: Summary of GAW10
46. Analysis of GNAZ gene polymorphism in bipolar affective disorder
47. Evidence for an association between a G protein beta3-gene variant with depression and response to antidepressant treatment
48. Association analysis of a functional G protein beta3 subunit gene polymorphism (C825T) in mood disorders
49. Identifying a series of candidate genes for mania and psychosis: A convergent functional genomics approach
50. Analysis of complex brain disorders with gene expression microarrays: Schizophrenia as a disease of synapse
51. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia
52. Application of cDNA microarrays to examine gene expression differences in schizophrenia
53. Disease-specific alteration in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder
54. Towards behavioral genomics
55. Proteomics in neuropsychiatric disorders
56. Diagnostic subgrouping of depressed patients by principal component analysis and visualized pattern recognition
57. Association between the 5′ UTR variant C1785 of the serotonin receptor gene HTR3A and bipolar disorder
58. Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder
59. What does it mean to identify a protein in proteomics?
60. The human genome:proteomics
61. A post-genomic challenge: Learning to read patterns of protein synthesis